Literature DB >> 1453152

Gastroesophageal reflux disease in adults: pathophysiology, diagnosis, and management.

D K Rex1.   

Abstract

Gastroesophageal reflux disease (GERD) refers to symptoms or tissue damage that result from gastroesophageal reflux. Reflux esophagitis is a subset of GERD and implies the presence of esophageal inflammation, ie, esophageal erosions that are visible endoscopically, or nonerosive inflammation that can be documented by biopsies. Heartburn is the most common and specific symptom of GERD. In some patients, chest pain or respiratory symptoms may be the only presenting signs. In patients aged < 50 years with uncomplicated GERD, empiric therapy (typically with antacids or an H2-receptor antagonist) is appropriate. For older patients, those with complications, and those whose symptoms do not respond to empiric therapy, endoscopic evaluation is indicated. Many patients will improve with standard twice-daily dosing of an H2-receptor antagonist. However, GERD is generally more resistant to antisecretory pharmacologic therapy than is peptic ulcer disease. Those patients who fail to respond to standard dosing of an H2-receptor antagonist may get relief from high-dose H2-receptor antagonists or omeprazole therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1453152

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  3 in total

1.  A review of reflux esophagitis around the world.

Authors:  Edwin J Zarling
Journal:  World J Gastroenterol       Date:  1998-08       Impact factor: 5.742

2.  Tororo project.

Authors:  J Lewis
Journal:  Can Fam Physician       Date:  1993-03       Impact factor: 3.275

3.  Molecular Mechanism of the Effect of Zhizhu Pill on Gastroesophageal Reflux Disease Based on Network Pharmacology and Molecular Docking.

Authors:  Jinke Huang; Yitian Wang; Peng Xu; Jiali Liu; Jinxin Ma; Yu Wang; Zhihong Liu; Mi Lv; Fengyun Wang; Xudong Tang
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-19       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.